Skip to main content

Table 1 Characteristics of included trials by anticancer drug type

From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

  ICPi (n = 3) Other anticancer drug (n = 10)
Included drugs (n) Ipilimumab, Pembrolizumab, Nivolumab Abiraterone acetate, Brentuximab vedotin, Bosutinib, Ziv-aflibercept, Dabrafenib, Afatinib, Belinostat, Ramucirumab, Blinatumomab, Olaparib
Drug approval characteristics, n (%) Priority review 0, orphan drug 3 (100%), breakthrough therapy 2 (67%), accelerated approval 2 (67%) Priority review 4 (40%), orphan drug 7 (70%), breakthrough therapy 1 (10%), accelerated approval 4 (40%)
  ICPi trials (n = 19) Other anticancer drug trials (n = 101)
Study phase, n (%)
 Phase 1 5 (26) 42 (42)
 Phase 2 9 (47) 48 (48)
 Phase 3 5 (26) 11 (11)
Efficacy study, n (%) 11 (58) 18 (18)
Randomized study, n (%) 12 (63) 28 (28)
Double-blinded study, n (%) 7 (37) 13 (13)
Multi-country study, n (%) 12 (63) 52 (51)
Author affiliation with industry, n (%) 18 (95) 82 (81)
Sample size, median (IQR) 284 (127–676) 58 (37–121)
Statistically significant outcomeª, n (%) 8 (42) 10 (10)
Reporting of adverse events, n (%) 19 (100) 91 (90)
Selective outcome reporting, n (%) 6 (32) 21 (21)
  1. ICPi immune checkpoint inhibitor, IQR interquartile range
  2. ªAt least 1 of the primary outcomes was statistically significant
\